-

LU Investor Alert: Lufax Holding Ltd Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Falsified SOX Certifications: Levi & Korsinsky

Important Information Regarding Section 20(a) Individual Liability Claims Against Lufax's CEO and CFO

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Lufax Holding Ltd (NYSE: LU) of a pending securities class action naming two senior officers as individual defendants. Class Period: April 7, 2023 through January 26, 2025. Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.

Lufax ADS holders lost $0.40 per share (13.8%) on the initial corrective disclosure, with cumulative declines pushing shares from $2.89 to $2.26 over three trading sessions. A re-audit confirmed net profit overstatements of RMB 917.0 million (2022) and RMB 81.4 million (2023). The Court has set May 20, 2026 as the deadline to apply for lead plaintiff appointment.

The Named Individual Defendants

The securities action identifies Yong Suk Cho, who served as Chief Executive Officer at all relevant times, and David Siu Kam Choy, who served as Chief Financial Officer until April 2024. Both officers directly participated in Company management and were involved in drafting, reviewing, and disseminating the allegedly false annual reports filed with the SEC.

Sarbanes-Oxley Certification Obligations

The complaint charges that both Cho and Choy signed SOX certifications attached to the 2022 and 2023 Annual Reports on Form 20-F. Those certifications attested to:

  • The accuracy of Lufax's financial reporting for fiscal years 2022 and 2023
  • The effectiveness of the Company's disclosure controls and procedures
  • The effectiveness of internal control over financial reporting under the COSO 2013 framework
  • The disclosure of any material changes to internal controls
  • The disclosure of all fraud involving management or employees with a significant role in internal controls

The action contends these certifications were materially false because Lufax's internal controls were deficient, and the resulting financial statements overstated net profit by nearly RMB 1 billion across two fiscal years.

Section 20(a) Control Person Framework

The lawsuit asserts that Cho and Choy are liable as "controlling persons" under Section 20(a) of the Securities Exchange Act of 1934. As pleaded, both officers exercised power and authority over the contents of Lufax's SEC filings, press releases, and public statements throughout the Class Period. Their positions gave them access to confidential information about the Company's true financial condition, including the adequacy of internal controls and the existence of the Subject Transactions that PricewaterhouseCoopers later flagged.

Speak with an attorney about recovering damages or call (212) 363-7500.

"Corporate officers have a duty to ensure their companies' public statements are accurate and complete. When SOX certifications attest to effective internal controls that are later found deficient, and when net profit is overstated by hundreds of millions of RMB, the officers who signed those certifications face serious questions about their liability." -- Joseph E. Levi, Esq.

Submit your information to join the recovery or contact Joseph E. Levi, Esq. at (212) 363-7500.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Levi & Korsinsky, LLP

NYSE:LU

Release Versions

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

More News From Levi & Korsinsky, LLP

EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)

NEW YORK--(BUSINESS WIRE)--Roughly seven out of every ten dollars invested in EyePoint Pharmaceuticals (NASDAQ: EYPT) common stock was wiped out when shares fell nearly 67% following the Company's disclosure that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO wet AMD trial. If you held EYPT shares through that decline, you are encouraged to have your EYPT losses reviewed now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at...

GLOB Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Globant (GLOB)

NEW YORK--(BUSINESS WIRE)--Shareholders of Globant (NYSE: GLOB) absorbed a sharp decline in the shares after the Company's Q2 2026 earnings release, which reported revenue of approximately $614.4 million and a reduced full-year 2026 revenue forecast. Investors who lost money on GLOB are encouraged to request a review of your GLOB losses now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The reported quarter came in below street...

PRIM Deadline Alert: Levi & Korsinsky Reminds Primoris Services Corporation (PRIM) Investors of Securities Class Action Deadline on September 21, 2026

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP notifies investors in Primoris Services Corporation (NYSE: PRIM) that a class action has been filed on behalf of shareholders who purchased securities between August 5, 2025 and June 22, 2026. See if you could be eligible to recover or call (212) 363-7500.PRIM fell $23.39 per share, or 21.6%, from $108.34 to $84.95 on June 23, 2026. The lead plaintiff deadline is September 21, 2026.Primoris Timeline Disclosure Events Alleged in the ComplaintTh...
Back to Newsroom